Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Recurrent Pericarditis: early-phase trial registry

4 of 5 indexed Recurrent Pericarditis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 4 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Recurrent Pericarditis: 5 US clinical trials tracked, 4 recruiting.

Recurrent Pericarditis is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Kiniksa Pharmaceuticals International, running 3 of these trials.

Enrollment posture brief

Registry condition recurrent-pericarditis

OPEN 4 | RECR 80% | LATE 1 | EARLY 3 | RANK #3391 | SPON 3

Nearest open-share peer: Acute Leukemia of Ambiguous Lineage (80% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Recurrent Pericarditis (this)80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Recurrent Pericarditis

Recurrent Pericarditis lists 4 open slots (80% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Recurrent Pericarditis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Recurrent Pericarditis is recruiting above its size-band peers.

    4 of 5 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Recurrent Pericarditis research.

    Kiniksa Pharmaceuticals International accounts for 3 of 5 trials (60%). 3 distinct sponsors appear on at least one study for this condition label.

  3. Typical Recurrent Pericarditis enrolment sits around 110 participants.

    Median target enrolment is 110 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.

  4. Recurrent Pericarditis research is mostly interventional.

    4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 23Phase 31

Phase Distribution

PhaseTrial count
Phase 2 3
Phase 3 1

Named interventions

Most-linked intervention names on Recurrent Pericarditis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

KPL-387 Drug
2 trials
VTX2735 Drug
1 trials
CardiolRx Drug
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Recurrent Pericarditis trials. A trial with sites in several states counts in each.

New York 5 trials
California 5 trials
Virginia 4 trials
Texas 4 trials
Ohio 4 trials
Minnesota 4 trials
Illinois 4 trials
Arizona 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Recurrent Pericarditis page

5 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Pericarditis condition card totals 5 registered trials; most-linked intervention KPL-387; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.